Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
van Heeckeren
Willem J
WJ
Ortiz
Jose
J
Cooney
Matthew M
MM
Remick
Scot C
SC
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D017321:Clinical Trials, Phase I as Topic; D017277:Drug Approval; D016503:Drug Delivery Systems; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D008297:Male; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D011379:Prognosis; D011507:Proteinuria / Q000139:chemically induced*; D018570:Risk Assessment; D015398:Signal Transduction / Q000187:drug effects; D016019:Survival Analysis; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000502:physiology
D020533:Angiogenesis Inhibitors; D015415:Biomarkers; D042461:Vascular Endothelial Growth Factor A